Cytokine Therapy for Arterial Restenosis: Inhibition of Neointimal Hyperplasia by Gamma-Interferon

Abstract

Inhibition of neointimal hyperplasia by gamma-interferon (gIFN) treatment was evaluated. Four groups of Sprague-Dawley rats (n= 72) weighing 500 g underwent endothelial injury of the carotid artery using the previously described Fogarty catheter technique. Group I (controls, n = 8) received one phosphate-buffered saline (PBS) injection 24 h before injury and every 24 h thereafter for a total of eight injections. Groups II (n = 8) and III (n = 8) received daily injections of 200000 units of gIFN according to the same schedule except that group III did not receive the preoperative dose. Animals were Killed on postoperative day 14. Histologic sections were analyzed morphometrically and immunohistochemically. Both gIFN groups had a statistically significant 50% reduction of the cross-sectional area of the neointimal hyperplasia compared with that of the controls (P< 0.01). Cell replication analysis of smooth muscle cells in the media and neointima revealed no statistically significant difference between controls and gIFN-treated groups. Group IV consisted of 48 rats that were treated with either PBS or gIFN on a schedule similar to that of groups I and II. Animals were killed at frequent time intervals during the first 7 days after injury. Their arteries were analyzed histologically and immunohistochemically. The results confirm previous findings that gIFN reduces the development of neointimal hyperplasia following arterial injury. The results also indicate that smooth muscle cells restore their proliferative activity by 7 days after discontinuation of gIFN treatment. It is proposed that efficacy of gIFN can be enhanced by lengthening the period of treatment.

Keywords

artery neointimal hyperplasia interferon

Get full access to this article

View all access options for this article.

References

Clowes

. Pathologic intimal hyperplasia as a response to vascular injury and reconstruction. In: Rutherford

, ed. Vascular Surgery. Philadelphia: WB Saunders, 1989: 266–75.

Clagett

. Morphogenesis and clinicopathologic characteristics of recurrent carotid disease. J Vasc Surg 1986; 3: 10–23.

Healy

Zierler

Nicholls

Long-term follow-up and clinical outcome of carotid restenosis. J Vasc Surg 1989; 10: 662–9.

McBride

Lange

Hillis

. Restenosis after successful coronary angioplasty: pathophysiology and prevention. N Engl J Med 1988; 318: 1734–7.

Clowes

Reidy

Clowes

. Mechanisms of stenosis after arterial injury. Lab Invest 1983; 49: 208–15.

Schwartz

Campbell

. Replication of smooth muscle cells in vascular disease. Circ Res 1986; 58: 427–44.

Clowes

Schwartz

. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res 1985; 56: 139–45.

Majack

Majesky

Goodman

. Role of PDGF-A expression in the control of vascular smooth muscle cell growth by transforming growth factor-B. J Cell Biol 1990; 111: 239–47.

Lindner

Lappi

Baird

Majack

Reidy

. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991; 68: 106–13.

10.

McNeil

Muthurishnan

Warder

D'Amore

. Growth factors are released by mechanically wounded endothelial cells. J Cell Biol 1989; 109: 811–22.

11.

Fingerle

Johnson

Clowes

Majesky

Reidy

. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid injury. Proc Natl Acad Sci U S A 1989; 86: 8412–16.

12.

Olson

Chao

Lindner

Reidy

. Intimal smooth muscle cell proliferation after balloon catheter injury. Am J Pathol 1992; 140: 1017–23.

13.

Chervu

Moore

Quinones-Baldrich

Henderson

. Efficacy of corticosteroids in suppression of intimal hyperplasia. J Vasc Surg 1989; 10: 129–34.

14.

Dryjski

Mikat

Bjornsson

. Inhibition of intimal hyperplasia after arterial injury by heparin and heparinoid. J Vasc Surg 1988; 8: 623–33.

15.

Clowes

Karnovsky

. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977; 265: 625–6.

16.

Powell

Müller

RKM

Rouge

Kuhn

Heftik

Baumgartner

. The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition. J Cardiovasc Pharmacol 1990; 16(Suppl 4): 542–9.

17.

Schwartz

Lesperance

Bourassa

. The role of antiplatelet agents in modifying the extent of restenosis following percutaneous transluminal coronary angioplasty. Am Heart J 1990; 119: 232–6.

18.

Schlant

King

III . Usefulness of calcium entry blockers during and after percutaneous transluminal coronary artery angioplasty. Circulation 1989; 80(Suppl IV): 88–92.

19.

Clowes

. The role of aspirin in enhancing arterial graft patency. J Vasc Surg 1986; 3: 381–5.

20.

Hansson

Holm

. Interferon-g inhibits arterial stenosis after injury. Circulation 1991; 84: 1–6.

21.

Clowes

Reidy

Clowes

. Kinetics of cellular proliferation after arterial injury. Smooth muscle cell growth in the absence of endothelium. Lab Invest 1983; 49: 327–33.

22.

Travali

Rizzo

Structure of the human gene for the proliferating cell nuclear antigen. J Biol Chem 1989; 264: 7466–72.

23.

Takasaki

Fishwild

Tan

. Characterization of proliferating cell nuclear antigen recognized by autoantibodies in lupus sera. J Exp Med 1984; 159: 981–92.

24.

Mathews

Bernstein

Franza

Jr Garrels

. Identity of the proliferating cell nuclear antigen and cyclin. Nature 1984; 309: 374–6.

25.

Waseem

Lane

. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). J Cell Science 1990; 96: 121–9.

26.

Garcia

Coltrera

Gown

. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibiodies in fixed, embedded tissues. Am J Pathol 1989; 134: 733–9.

27.

Galand

Degraef

. Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labelling for marking S-phase cells in paraffin sections from animal and human tissues. Cell Tissue Kinet 1989; 22: 383–92.

28.

Baron

Grossberg

Klimpel

Brunell

. Immune and interferon systems. In: Galasso

Merigan

Buchanan

, eds. Antiviral Agents and Viral Diseases of Man. New York: Raven Press, 1984: 123–78.

29.

Grossberg

Taylor

Siebenlist

Jameson

. Biological and Immunological assays of human interferons. In: Rose

Friedman

Fahey

, eds. Manual of Clinical Laboratory Immunology, 3rd ed. Washington DC: American Society for Microbiology, 1986: 295–303.

30.

Clark

Brater

Johnson

. Principles of immunopharmacology. In: Kist

, ed. Goth's Medical Pharmacology. 13th ed. St Louis: Mosby-Year Book, 1992: 716–29.

31.

Nathan

. Secretory products of macrophages. J Clin Invest 1987; 79: 319–26.

32.

Hansson

Jonasson

Holm

Clowes

. Gamma-interferon regulates vascular smooth muscle proliferation and Ia antigen expression in vivo and in vitro. Circ Res 1988; 63: 712–19.

33.

Hansson

Holm

Foteve

Hedrich

Fingerle

. T-lymphocytes inhibit the vascular response to injury. Proc Natl Acad Sci U S A 1991; 88: 1–5.

34.

Clowes

Reidy

. Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia — a review. J Vasc Surg 1991; 13: 885–91.

35.

Nunokawa

Tanaka

. Interferon-gamma inhibits proliferation of rat vascular smooth muscle cells by nitric oxide generation. Biochem Biophys Res Commun 1992; 188: 409–15.

36.

Warner

SJC

Friedman

Libby

. Immune interferon inhibits proliferation and induces 2′–5′-oligoadenylate synthetase gene expression in human vascular smooth muscle cells. J Clin Invest 1989; 83: 1174–82.

37.

Hansson

Hellstrand

Rymo

Rubbia

Gabbiani

. Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha smooth muscle actin in arterial smooth muscle cells. J Exp Med 1989; 170: 1595–608.